⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Ascilion AB and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Ascilion AB
↗Kista, Sweden
Ascilion is a Swedish biotechnology company and a global leader in the development of dermal interstitial fluid (dISF) sampling technology. Founded in 2012, the company utilizes proprietary hollow microneedle technology to enable painless, reliable, and efficient extraction of dISF for biomarker analysis, diagnostics, and wearable health monitoring applications.
The company's core product, the PELSA device, is designed to support pharmaceutical development, clinical research, and biosensor development. By bridging precision engineering with biomarker science, Ascilion aims to democratize healthcare monitoring by providing a minimally invasive alternative to traditional blood sampling.
CLASSIFICATION
Company Type:MedTech
Therapeutic Areas:
Industry:Biotechnology
Sub-Industry:Medical Devices / Diagnostics
SIZE & FINANCIALS
Employees:1-50
Founded:2012
Ownership:private
Status:operating
FUNDING
Stage:Venture - Series Unknown
Total Raised:$2.2M
Investors:Lotus One Investment Pte. Ltd.
PIPELINE
Stage:Commercial
Lead Drug Stage:N/A (Device/Platform Technology)
Modalities:Microneedle-based sampling, Microfluidics
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Indero (CRO partner for clinical trials), Charité University (Heart failure research), Incyte Corporation (Atopic dermatitis evaluation), Cari Health (Remote medication monitoring)
COMPETITION
Position:Niche Player
Competitors:Cordance Medical, Bioactivx, DefEYE
LEADERSHIP
Key Executives:
Simon Grant - CEO
Pelle Rangsten - Co-founder & CTO
Board Members:Sten Dahlborg (Chairman), Asmita Dwivedi
LINKS
Website:ascilion.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Ascilion AB. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.